A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

NCT00526617 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-hematologic Malignancies
Metastatic Melanoma
Breast Cancer
Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer
Hepatocellular Carcinoma

Interventions

DRUG: ABT-888
DRUG: Temozolomide

Sponsor

AbbVie